Skip to main content
OpenTrials
Completed

NCT Number: NCT07276347

Comprehensive Assessment of Multiple Products (CAMP)

The aim of this study is to assess contact lens performance and acceptance.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Indiana University

Bloomington, Indiana, 47405, United States

About this study

The objective of this study is to assess the initial performance and acceptance of a range of contact lenses in habitual soft contact lens wearers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 to 45 years (inclusive)
  • Habitual soft spherical contact lens wearer (current prescription)
  • Refractive error of -6.00 to -0.50DS or +0.50 to +6.00DS and less than or equal to 0.75DC as vertexed to the corneal plane
  • Anisometropia no greater than 1.50D, based on vertexed manifest refraction spherical equivalent
  • Can achieve visual acuity of at least 20/25 in each eye with spherical equivalent manifest refraction

Exclusion criteria

  • Active anterior segment infection, inflammation or abnormality that would contraindicate contact lens wear
  • Use of systemic or ocular medication that would contraindicate contact lens wear
  • Used gas permeable/hard contact lenses (including orthokeratology) in the previous 3 months
  • Participation in a contact lens or lens care product trial in the previous 30 days

Treatment and study plan

somofilcon A lens

Device

Participants will be randomized to wear somofilcon A soft contact lens for 10 hours.

stenfilcon A lens

Device

Participants will be randomized to wear stenfilcon A soft contact lens for 10 hours.

fanfilcon A lens

Device

Participants will be randomized to wear fanfilcon A soft contact lens for 10 hours.

comfilcon A lens

Device

Participants will be randomized to wear comfilcon A soft contact lens for 10 hours.

verofilcon A lens

Device

Participants will be randomized to wear verofilcon A soft contact lens for 10 hours.

serafilcon A lens

Device

Participants will be randomized to wear serafilcon A soft contact lens for 10 hours.

lehfilcon A lens

Device

Participants will be randomized to wear lehfilcon A soft contact lens for 10 hours.

delefilcon A lens

Device

Participants will be randomized to wear delefilcon A soft contact lens for 10 hours.

senofilcon A daily disposable lens

Device

Participants will be randomized to wear senofilcon A soft contact lens for 10 hours.

senofilcon A with blue light technology lens

Device

Participants will be randomized to wear senofilcon A soft contact lens for 10 hours.

senofilcon A bi-weekly lens

Device

Participants will be randomized to wear senofilcon A soft contact lens for 10 hours.

samfilcon A lens

Device

Participants will be randomized to wear samfilcon A soft contact lens for 10 hours.

kalilfilcon A lens

Device

Participants will be randomized to wear kalifilcon A soft contact lens for 10 hours.

Primary outcomes

  1. High contrast, high luminance binocular distance visual acuity

    Time frame: At the end of 10 hours of daily wear at dispensing

    High contrast, high luminance binocular distance visual acuity (logMAR) will be measured at 10-hour visit.

Sponsors and collaborators

Lead sponsor

CooperVision International Limited (CVIL)

Industry

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 11, 2025
Registry last updated
Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.